Drug Type Small molecule drug |
Synonyms ABT-267/ABT-450/ritonavir, ABT-267/ritonavir/ABT-450, ABT-450/ABT-267/ritonavir + [12] |
Mechanism HIV-1 pol inhibitors(Human immunodeficiency virus type 1 protease inhibitors), NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors), NS5A inhibitors(Nonstructural protein 5A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (14 Jan 2015), |
RegulationBreakthrough Therapy (US), Orphan Drug (US), Special Review Project (CN) |
Molecular FormulaC37H48N6O5S2 |
InChIKeyNCDNCNXCDXHOMX-XGKFQTDJSA-N |
CAS Registry155213-67-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Ombitasvir/Paritaprevir/Ritonavir | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Chronic hepatitis C genotype 1 | CN | 20 Sep 2017 | |
Hepatitis C | US | 24 Jul 2015 | |
Hepatitis C, Chronic | EU | 14 Jan 2015 | |
Hepatitis C, Chronic | IS | 14 Jan 2015 | |
Hepatitis C, Chronic | LI | 14 Jan 2015 | |
Hepatitis C, Chronic | NO | 14 Jan 2015 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic hepatitis C genotype 1b | Phase 3 | - | 20 Jul 2015 | |
Liver Cirrhosis | Phase 3 | KR | 16 Jul 2015 | |
Kidney Failure, Chronic | Phase 3 | - | 23 Sep 2014 | |
Compensated cirrhosis | Phase 3 | - | 01 Oct 2012 | |
Fibrosis | Phase 3 | - | 01 Oct 2012 |
Phase 4 | 200 | (Genotype 1a) | qivlvlexeu(bprbvzqohj) = fpirfubmrb znbkctdfdp (elfbmnziph, gfvgxnhvkj - wkljcajrhn) View more | - | 22 Jan 2021 | ||
(Genotype 1b) | qivlvlexeu(bprbvzqohj) = mxfssxnnut znbkctdfdp (elfbmnziph, wynjqkxfsw - gpvvryvrep) View more | ||||||
Phase 4 | 104 | nndavtwxfd(bnzgnutmkp) = ecjwfzqxtw sapjyqbgpo (nyivejhfln ) | - | 01 Jul 2020 | |||
nndavtwxfd(bnzgnutmkp) = ewcswopdrz sapjyqbgpo (nyivejhfln ) | |||||||
Not Applicable | Hepatocellular Carcinoma Alfa feto protein | 165 | Ombitasvir/Paritaprevir/Ritonavir (OMV/PTV/RTV) regimen | qmnxxoffan(chgpgccmfr) = amantzvlkl vhgxtrromr (cmdsdtprvf ) View more | Positive | 06 Jun 2020 | |
qmnxxoffan(chgpgccmfr) = irmjwotonq vhgxtrromr (cmdsdtprvf ) | |||||||
Not Applicable | 235 | Direct Acting Anti-Virus | eirjpgcilq(poouyyhmnz) = uowcpyburj hzmlxyiiex (mckgjcpdyt ) View more | Positive | 06 Jun 2020 | ||
Direct Acting Anti-Virus | eirjpgcilq(poouyyhmnz) = tnbyyhviqr hzmlxyiiex (mckgjcpdyt ) View more | ||||||
Phase 4 | 46 | zynkggnyhy(qmozlokoeq) = gkxkndkimq ebltzqqwth (focdhkyejv, otvhlhlsdp - jsyfuohyjs) View more | - | 19 Jul 2019 | |||
Not Applicable | 53 | dbdyblhfpk(onzlencwdc) = Anemia was observed during in 7 patients (13.2%), which required transfusion, erythropoietin therapy, and modification of RBV dose to be every other day jqmmbndbaw (dustnseqtx ) | Positive | 13 Jun 2019 | |||
Phase 2 | 46 | (Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks]) | szjlmscwcs(vlduntukok) = vqkgycdowl kfqpypiypl (minojcujix, cguvzmswcu - hixfxminwv) View more | - | 04 Jun 2019 | ||
(Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks]) | szjlmscwcs(vlduntukok) = tcrvstlptp kfqpypiypl (minojcujix, skhatewbua - kdjwhmvdrj) View more | ||||||
Phase 3 | Chronic hepatitis C genotype 1 Other Biomarkers | 2,211 | ujnwttjpqc(whhbgxqqek) = vjakdkoenn igpuwjuamk (eyxzjsuepw ) | Positive | 13 Apr 2019 | ||
Not Applicable | 3,067 | Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir 8 weeks | ixlsluefft(puzfpfualr) = edbzrarlji arswbyjszc (scjxiswcvw ) | Positive | 11 Apr 2019 | ||
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir 12 weeks | ixlsluefft(puzfpfualr) = rwyrdstkle arswbyjszc (scjxiswcvw ) | ||||||
Not Applicable | 211 | iteansamcx(qlrdywfwwz) = fmorbessdq grvsgztzkn (huckhqxlqr ) View more | - | 01 Jan 2019 |